Online inquiry

IVTScrip™ mRNA-Anti-DLL4, REGN-421(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14081MR)

This product GTTS-WQ14081MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets DLL4 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_019074.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 54567
UniProt ID Q9NR61
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-DLL4, REGN-421(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14081MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4185MR IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BI-754111
GTTS-WQ14357MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RG7716
GTTS-WQ3807MR IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BB-10901
GTTS-WQ1523MR IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACE-031
GTTS-WQ7643MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN-1029(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GEN-1029
GTTS-WQ13706MR IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA RC48
GTTS-WQ1655MR IVTScrip™ mRNA-Anti-GP6, ACT-017(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ACT-017
GTTS-WQ4567MR IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-936564
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW